Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

NCT02665416 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG: Selicrelumab
DRUG: Vanucizumab
DRUG: Bevacizumab

Sponsor

Hoffmann-La Roche